Skip to content 
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California. more
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| EVMN | |
|---|---|
| ROA (LTM) | 0.00% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| EVMN | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Evommune, Inc. (EVMN) share price today is $18.01
Yes, Indians can buy shares of Evommune, Inc. (EVMN) on Vested. To buy Evommune, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EVMN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Evommune, Inc. (EVMN) via the Vested app. You can start investing in Evommune, Inc. (EVMN) with a minimum investment of $1.
You can invest in shares of Evommune, Inc. (EVMN) via Vested in three simple steps:
The 52-week high price of Evommune, Inc. (EVMN) is $24.03. The 52-week low price of Evommune, Inc. (EVMN) is $16.7.
The price-to-book (P/B) ratio of Evommune, Inc. (EVMN) is 0.00
The market capitalization of Evommune, Inc. (EVMN) is $592.23M
The stock symbol (or ticker) of Evommune, Inc. is EVMN
Link copied 
